Furthermore, patients with tumors that were positive for HIF1α were at a 10-fold higher risk of developing castrate resistance (p = 0.021) and 9.8-fold higher risk of progressing to metastatic prostate cancer (p = 0.017) than patients not expressing HIF1α. This evidence concerns the gene HIF1A and metastatic prostate carcinoma.